First Quadrant’s Emergent Biosolutions EBS Stock Holding History

First Quadrant’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-672	Closed	-$39K	–	749
2020 Q1	$39K	Buy	+672	New	+$38.7K	0.01%	552
2019 Q1	–	Sell	-5,695	Closed	-$338K	–	729
2018 Q4	$338K	Sell	5,695 -3,284	-37%	-$212K	0.03%	425
2018 Q3	$591K	Hold	8,979	–	–	0.01%	463
2018 Q2	$453K	Hold	8,979	–	–	0.01%	504
2018 Q1	$473K	Sell	8,979 -3,329	-27%	-$166K	0.01%	491
2017 Q4	$572K	Buy	12,308 +8,431	+217%	+$355K	0.01%	520
2017 Q3	$157K	Buy	+3,877	New	+$140K	﹤0.01%	745
2014 Q2	–	Sell	-52,100	Closed	-$1.32M	–	810
2014 Q1	$1.32M	Buy	52,100 +11,600	+29%	+$293K	0.03%	343
2013 Q4	$931K	Buy	40,500 +37,400	+1,206%	+$780K	0.02%	392
2013 Q3	$59K	Buy	+3,100	New	+$55.3K	﹤0.01%	659

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Quadrant's EBS Position: Q2 2020 in Review

First Quadrant sold out of Emergent Biosolutions (EBS) in Q2 2020, closing a stake of 672 shares — an estimated $39K sold.

First Quadrant first reported a position in EBS in Q3 2013 and held it in 10 quarters. The position peaked at $1.32M in Q1 2014. 299 funds tracked by Wall St. Rank hold EBS as of Q2 2020.

First Quadrant reported no remaining Emergent Biosolutions position as of Q2 2020 after selling out during the quarter.
First Quadrant sold 672 Emergent Biosolutions shares in Q2 2020, an estimated $39K.
First Quadrant first reported a position in Emergent Biosolutions in Q3 2013 and held it in 10 quarters.
First Quadrant's Emergent Biosolutions position peaked at $1.32M in Q1 2014.
299 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2020.

Based on First Quadrant's 13F filing for Q2 2020, filed 28 Jul 2020.